Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MZE782 in adults with phenylketonuria
NL-OMON61657Phase 2Not yet recruiting
- Sponsor
- Maze Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MZE782 in phenylketonuria (PKU) (5 cohorts), sponsored by Maze Therapeutics. Primary endpoints: Absolute change in plasma phenylalanine from baseline to mean of Weeks 2, 3, and 4 and Safety and tolerability. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
MZE782
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON61657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61657.